Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2.
nephrocalcinosis
oxalate
primary hyperoxaluria
stone
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
25 04 2022
25 04 2022
Historique:
received:
13
07
2020
pubmed:
6
2
2021
medline:
27
4
2022
entrez:
5
2
2021
Statut:
ppublish
Résumé
Primary hyperoxaluria (PH) type 3 (PH3) is caused by mutations in the hydroxy-oxo-glutarate aldolase 1 gene. PH3 patients often present with recurrent urinary stone disease in the first decade of life, but prior reports suggested PH3 may have a milder phenotype in adults. This study characterized clinical manifestations of PH3 across the decades of life in comparison with PH1 and PH2. Clinical information was obtained from the Rare Kidney Stone Consortium PH Registry (PH1, n = 384; PH2, n = 51; PH3, n = 62). PH3 patients presented with symptoms at a median of 2.7 years old compared with PH1 (4.9 years) and PH2 (5.7 years) (P = 0.14). Nephrocalcinosis was present at diagnosis in 4 (7%) PH3 patients, while 55 (89%) had stones. Median urine oxalate excretion was lowest in PH3 patients compared with PH1 and PH2 (1.1 versus 1.6 and 1.5 mmol/day/1.73 m2, respectively, P < 0.001) while urine calcium was highest in PH3 (112 versus 51 and 98 mg/day/1.73 m2 in PH1 and PH2, respectively, P < 0.001). Stone events per decade of life were similar across the age span and the three PH types. At 40 years of age, 97% of PH3 patients had not progressed to end-stage kidney disease compared with 36% PH1 and 66% PH2 patients. Patients with all forms of PH experience lifelong stone events, often beginning in childhood. Kidney failure is common in PH1 but rare in PH3. Longer-term follow-up of larger cohorts will be important for a more complete understanding of the PH3 phenotype.
Sections du résumé
BACKGROUND
Primary hyperoxaluria (PH) type 3 (PH3) is caused by mutations in the hydroxy-oxo-glutarate aldolase 1 gene. PH3 patients often present with recurrent urinary stone disease in the first decade of life, but prior reports suggested PH3 may have a milder phenotype in adults. This study characterized clinical manifestations of PH3 across the decades of life in comparison with PH1 and PH2.
METHODS
Clinical information was obtained from the Rare Kidney Stone Consortium PH Registry (PH1, n = 384; PH2, n = 51; PH3, n = 62).
RESULTS
PH3 patients presented with symptoms at a median of 2.7 years old compared with PH1 (4.9 years) and PH2 (5.7 years) (P = 0.14). Nephrocalcinosis was present at diagnosis in 4 (7%) PH3 patients, while 55 (89%) had stones. Median urine oxalate excretion was lowest in PH3 patients compared with PH1 and PH2 (1.1 versus 1.6 and 1.5 mmol/day/1.73 m2, respectively, P < 0.001) while urine calcium was highest in PH3 (112 versus 51 and 98 mg/day/1.73 m2 in PH1 and PH2, respectively, P < 0.001). Stone events per decade of life were similar across the age span and the three PH types. At 40 years of age, 97% of PH3 patients had not progressed to end-stage kidney disease compared with 36% PH1 and 66% PH2 patients.
CONCLUSIONS
Patients with all forms of PH experience lifelong stone events, often beginning in childhood. Kidney failure is common in PH1 but rare in PH3. Longer-term follow-up of larger cohorts will be important for a more complete understanding of the PH3 phenotype.
Identifiants
pubmed: 33543760
pii: 6129107
doi: 10.1093/ndt/gfab027
pmc: PMC9214566
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
869-875Subventions
Organisme : NCATS NIH HHS
ID : R21 TR003174
Pays : United States
Organisme : NIDDK NIH HHS
ID : U54 DK083908
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the ERA-EDTA.
Références
N Engl J Med. 2013 Nov 28;369(22):2163
pubmed: 24283239
Kidney Int. 2020 Apr;97(4):786-792
pubmed: 32093915
PLoS One. 2013 Aug 05;8(8):e70617
pubmed: 23940605
Clin Chem. 1991 Jul;37(7):1229-35
pubmed: 1855295
Am J Nephrol. 2005 May-Jun;25(3):290-6
pubmed: 15961949
Nephrol Dial Transplant. 2012 May;27(5):1729-36
pubmed: 22547750
Clin J Am Soc Nephrol. 2020 Jul 1;15(7):1056-1065
pubmed: 32165440
Kidney Int. 2015 Mar;87(3):623-31
pubmed: 25229337
J Urol. 2018 Mar;199(3):623-632
pubmed: 29061541
Pediatr Nephrol. 2015 Oct;30(10):1781-91
pubmed: 25519509
Kidney Int. 2001 Jan;59(1):31-6
pubmed: 11135054
Pediatr Nephrol. 2019 Oct;34(10):1785-1790
pubmed: 31123811
J Am Soc Nephrol. 2015 Oct;26(10):2559-70
pubmed: 25644115
JAMA. 2007 Nov 7;298(17):2038-47
pubmed: 17986697
JAMA Intern Med. 2019 Apr 1;179(4):542-551
pubmed: 30830167
Am J Hum Genet. 2010 Sep 10;87(3):392-9
pubmed: 20797690
Hum Mol Genet. 1999 Oct;8(11):2063-9
pubmed: 10484776
Clin J Am Soc Nephrol. 2011 Sep;6(9):2289-95
pubmed: 21896830
Eur J Hum Genet. 2013 Feb;21(2):162-72
pubmed: 22781098
Kidney Int. 2009 Jun;75(12):1264-1271
pubmed: 19225556
Urolithiasis. 2019 Feb;47(1):67-78
pubmed: 30430197
Pediatr Nephrol. 2015 Oct;30(10):1807-13
pubmed: 25972204
Pediatr Nephrol. 2018 Aug;33(8):1443-1446
pubmed: 29705963
Curr Opin Nephrol Hypertens. 2019 Jul;28(4):316-320
pubmed: 31045662
Lancet. 1986 Nov 15;2(8516):1168
pubmed: 2877320
Nat Rev Nephrol. 2012 Jun 12;8(8):467-75
pubmed: 22688746
Kidney Int. 2019 Dec;96(6):1389-1399
pubmed: 31685312
Nephrol Dial Transplant. 2016 May;31(5):798-806
pubmed: 26932693
Pediatr Nephrol. 2017 Dec;32(12):2263-2271
pubmed: 28711958
N Engl J Med. 2008 Jul 3;359(1):100-2
pubmed: 18596285
Clin J Am Soc Nephrol. 2016 Jan 7;11(1):119-26
pubmed: 26656319
Nephrol Dial Transplant. 2012 Aug;27(8):3024-6
pubmed: 22851625
Clin Chem. 2005 Dec;51(12):2377-80
pubmed: 16306102
J Nephrol. 1998 Mar-Apr;11 Suppl 1:51-5
pubmed: 9604812
Nephrol Dial Transplant. 2012 Aug;27(8):3191-5
pubmed: 22391140
Mayo Clin Proc. 2015 Oct;90(10):1356-65
pubmed: 26349951
J Urol. 1985 Dec;134(6):1242-4
pubmed: 3840540